Zai Lab (ZLAB) News Today $26.00 -0.05 (-0.19%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Market Sentiment Around Loss-Making Zai Lab Limited (NASDAQ:ZLAB)January 20 at 7:26 AM | finance.yahoo.comZai Lab Limited (NASDAQ:ZLAB) Position Decreased by JPMorgan Chase & Co.JPMorgan Chase & Co. reduced its holdings in Zai Lab Limited (NASDAQ:ZLAB - Free Report) by 43.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 138,125 shares of the company's stock after selling 10January 20 at 3:13 AM | marketbeat.comBank of America Securities Sticks to Their Buy Rating for Zai Lab (ZLAB)January 18 at 1:01 PM | markets.businessinsider.comZai Lab Jumps as Schizophrenia Drug OkayedJanuary 17, 2025 | baystreet.caZai Lab’s Robust Product Growth and Portfolio Expansion Drive Buy RecommendationJanuary 17, 2025 | markets.businessinsider.comBank of America Securities Sticks to Its Buy Rating for Zai Lab (ZLAB)January 17, 2025 | markets.businessinsider.comChinese regulators accept Zai Lab application for KarXTJanuary 17, 2025 | msn.comZai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of SchizophreniaJanuary 17, 2025 | businesswire.comHennion & Walsh Asset Management Inc. Acquires 41,128 Shares of Zai Lab Limited (NASDAQ:ZLAB)Hennion & Walsh Asset Management Inc. boosted its holdings in Zai Lab Limited (NASDAQ:ZLAB - Free Report) by 28.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 183,317 shares of the company's stoJanuary 16, 2025 | marketbeat.comZai Lab announces results from innovaTV 301 studyJanuary 16, 2025 | markets.businessinsider.comBank of America Securities Keeps Their Buy Rating on Zai Lab (ZLAB)January 16, 2025 | markets.businessinsider.comZai Lab to seek China approval for cervical cancer therapy after positive trial dataJanuary 15, 2025 | msn.comZai Lab Partners With MediLink Therapeutics To Develop Novel LRRC15 Antibody-Drug ConjugateJanuary 10, 2025 | markets.businessinsider.comZai Lab enters Tmalin license agreement with MediLink TherapeuticsJanuary 10, 2025 | markets.businessinsider.comZai Lab, Vertex Pharmaceuticals announce povetacicept license agreementJanuary 10, 2025 | markets.businessinsider.comZai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and SingaporeJanuary 10, 2025 | businesswire.comVertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and SingaporeJanuary 10, 2025 | businesswire.comZai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug ConjugateJanuary 9, 2025 | businesswire.comZai Lab (NASDAQ:ZLAB) Shares Gap Up - Still a Buy?Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Time to Buy?January 7, 2025 | marketbeat.comZai Lab Secures Debt Facility to Bolster Financial StandingJanuary 5, 2025 | tipranks.comRafael Amado Sells 7,583 Shares of Zai Lab Limited (NASDAQ:ZLAB) StockJanuary 3, 2025 | insidertrades.comInsider Selling: Zai Lab Limited (NASDAQ:ZLAB) Insider Sells 7,583 Shares of StockZai Lab Limited (NASDAQ:ZLAB - Get Free Report) insider Rafael Amado sold 7,583 shares of the business's stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $26.28, for a total transaction of $199,281.24. Following the sale, the insider now directly owns 33,834 shares of the company's stock, valued at approximately $889,157.52. The trade was a 18.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.January 2, 2025 | marketbeat.comZai Lab (NASDAQ:ZLAB) Shares Gap Down - Here's What HappenedZai Lab (NASDAQ:ZLAB) Shares Gap Down - What's Next?January 2, 2025 | marketbeat.comZai Lab (NASDAQ:ZLAB) Shares Gap Down - What's Next?Zai Lab (NASDAQ:ZLAB) Shares Gap Down - Time to Sell?December 27, 2024 | marketbeat.comZai Lab: Rapidly Improving Outlook Bodes Well For The FutureDecember 26, 2024 | seekingalpha.comZai Lab (NASDAQ:ZLAB) shareholders have endured a 59% loss from investing in the stock three years agoDecember 23, 2024 | finance.yahoo.comZai Lab Announces Participation in Investor Conference in January 2025December 12, 2024 | businesswire.comFmr LLC Sells 487,202 Shares of Zai Lab Limited (NASDAQ:ZLAB)Fmr LLC trimmed its stake in shares of Zai Lab Limited (NASDAQ:ZLAB - Free Report) by 43.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 644,859 shares of the company's stock after selling 487,202 shDecember 11, 2024 | marketbeat.comZai Lab Limited (NASDAQ:ZLAB) Holdings Boosted by Wellington Management Group LLPWellington Management Group LLP grew its stake in shares of Zai Lab Limited (NASDAQ:ZLAB - Free Report) by 18.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,436,606 shares of the company's stock after purchasing an aDecember 9, 2024 | marketbeat.comJanus Henderson Group PLC Increases Stake in Zai Lab Limited (NASDAQ:ZLAB)Janus Henderson Group PLC raised its holdings in shares of Zai Lab Limited (NASDAQ:ZLAB - Free Report) by 34.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,760,074 shares of the company's stock aDecember 4, 2024 | marketbeat.comBamco Inc. NY Has $46.02 Million Stake in Zai Lab Limited (NASDAQ:ZLAB)Bamco Inc. NY increased its position in shares of Zai Lab Limited (NASDAQ:ZLAB - Free Report) by 6.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,906,520 shares of the company's stock after purchasing an adDecember 3, 2024 | marketbeat.comZai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic CancerDecember 2, 2024 | businesswire.comZai Lab's AUGTYRO For ROS1+ NSCLC Added To China's National Reimbursement Drug ListNovember 28, 2024 | markets.businessinsider.comAlgert Global LLC Invests $1.67 Million in Zai Lab Limited (NASDAQ:ZLAB)Algert Global LLC acquired a new stake in shares of Zai Lab Limited (NASDAQ:ZLAB - Free Report) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 69,000 shares of the company's stock, valued at approximately $1,666,000November 28, 2024 | marketbeat.comZai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug ListNovember 27, 2024 | finance.yahoo.comZai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China's National Reimbursement Drug ListNovember 27, 2024 | businesswire.comZai Lab, Pfizer enter collaboration for XacduroNovember 21, 2024 | markets.businessinsider.comZai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO ® (Sulbactam-Durlobactam)November 21, 2024 | businesswire.comConnor Clark & Lunn Investment Management Ltd. Has $14.58 Million Stock Holdings in Zai Lab Limited (NASDAQ:ZLAB)Connor Clark & Lunn Investment Management Ltd. lifted its stake in Zai Lab Limited (NASDAQ:ZLAB - Free Report) by 26.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 604,153 shares of the company's stoNovember 21, 2024 | marketbeat.comZai Lab Announces Completion Of Offering Of About 7.8 Mln ADSs, Stock DownNovember 18, 2024 | markets.businessinsider.comZai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary SharesNovember 18, 2024 | businesswire.comFY2024 EPS Estimates for Zai Lab Increased by AnalystZai Lab Limited (NASDAQ:ZLAB - Free Report) - Research analysts at Cantor Fitzgerald upped their FY2024 earnings per share (EPS) estimates for shares of Zai Lab in a note issued to investors on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now forecasts that the company will post eaNovember 18, 2024 | marketbeat.comAnalyst Estimates: Here's What Brokers Think Of Zai Lab Limited (NASDAQ:ZLAB) After Its Third-Quarter ReportNovember 15, 2024 | finance.yahoo.comZai Lab 7.84M share Secondary priced at $25.50November 15, 2024 | markets.businessinsider.comWhy Zai Lab (ZLAB) Stock Is Trading HigherNovember 15, 2024 | benzinga.comZai Lab (NASDAQ:ZLAB) Sees Large Volume Increase - Still a Buy?Zai Lab (NASDAQ:ZLAB) Sees Unusually-High Trading Volume - Time to Buy?November 15, 2024 | marketbeat.comLeerink Partnrs Has Positive View of Zai Lab FY2024 EarningsZai Lab Limited (NASDAQ:ZLAB - Free Report) - Equities research analysts at Leerink Partnrs boosted their FY2024 EPS estimates for shares of Zai Lab in a research note issued to investors on Tuesday, November 12th. Leerink Partnrs analyst J. Chang now forecasts that the company will earn ($2.55)November 15, 2024 | marketbeat.comZai Lab Announces Pricing of Public Offering of American Depositary SharesNovember 14, 2024 | businesswire.comZai Lab Third Quarter 2024 Earnings: EPS Beats ExpectationsNovember 14, 2024 | finance.yahoo.comZai Lab (NASDAQ:ZLAB) Shares Gap Down - Should You Sell?Zai Lab (NASDAQ:ZLAB) Shares Gap Down - Time to Sell?November 14, 2024 | marketbeat.com Get Zai Lab News Delivered to You Automatically Sign up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter. Email Address ZLAB Media Mentions By Week ZLAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZLAB News Sentiment▼0.600.63▲Average Medical News Sentiment ZLAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZLAB Articles This Week▼124▲ZLAB Articles Average Week Get Zai Lab News Delivered to You Automatically Sign up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Sarepta Therapeutics News Vaxcyte News Qiagen News Roivant Sciences News Ascendis Pharma A/S News Blueprint Medicines News Revolution Medicines News BridgeBio Pharma News Lantheus News Legend Biotech News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ZLAB) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zai Lab Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Zai Lab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
